Archive for February 28th, 2012

CBRX issued CRL. RPRX to meet FDA in May + TLON OPXA AFFY news

Feb 28, 2012 No Comments by

Watson Pharmaceuticals, Inc. (NYSE: WPI) and Columbia Laboratories, Inc. (Nasdaq: CBRX)  received a complete response letter (CRL) for its New Drug Application (NDA 22-139) for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of […]

Daily News Read more